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1. Introduction 
Cerebral hyperperfusion syndrome (CHS) was first described by Sundt et al. (1981) as a 
clinical syndrome following carotid endarterectomy (CEA) characterized by headache, 
neurological deficit, and epileptic seizures that is not caused by cerebral ischemia.   
This chapter deals with this uncommon but not exceptional complication of endovascular 
treatment of the arteries that supply the brain. We use the term carotid artery stenting (CAS) 
to refer to stenting of the internal carotid artery (ICA) because most publications are 
centered on this artery. Moreover, we include angioplasty without stent placement in the 
term CAS to facilitate reading comprehension because the relation between endovascular 
treatment and CHS is related to revascularization itself rather than to stent placement per se.  
Given the high rate of ischemic brain disease in relation to carotid stenosis and the high 
prevalence of asymptomatic carotid stenosis, numerous publications discuss CHS in relation 
to CEA: the incidence in these series ranges from 0.3% to 2.2%. However, CAS has 
continually evolved in recent years to the point where, after more than 40 years’ experience, 
it is considered an alternative to CEA. Furthermore, the development of new materials for 
stents, filters for distal protection, dual antiplatelet treatment, and the learning curve are 
minimizing the short- and long-term adverse effects of CAS.  
Documented complications of CAS include cerebral embolism, hemodynamic compromise, 
vessel dissection, and early restenosis and occlusion, as well as the hyperperfusion 
syndrome we deal with in this chapter. Moreover, the spectacular increase in endovascular 
treatment has revealed that hyperperfusion syndrome can also occur after revascularization 
of other arteries, such as the vertebral arteries, the subclavian arteries, or even those located 
within the brain, mainly the middle cerebral artery (MCA).  
In this chapter we will begin by discussing the pathophysiology, clinical presentation, and 
incidence of CHS in the different published series. We will then discuss the risk factors, 
diagnostic methods, and strategies for prevention and treatment. We will also discuss a 
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condition that shares the same pathophysiology as CHS, contrast-induced encephalopathy, 
in which contrast agents crossing the blood-brain barrier have a toxic effect on the brain 
parenchyma, resulting in signs and symptoms similar to those of CHS. Given the larger 
number of publications about hyperperfusion after CEA and the obvious similarities in 
aspects like the pathophysiology and risk factors, we refer to CEA on numerous occasions in 
this chapter.  
2. Pathophysiology  
First, we must differentiate between the concept of hyperperfusion and CHS. In general, 
hyperperfusion is considered to occur when cerebral blood flow (CBF) in the revascularized 
territory increases by 100% or more with respect to the baseline values. In series by 
Ogasawara (2007) and Fukuda (2007), 16.7% to 28.6% of the patients with an increase in CBF 
100% developed CHS. Moreover, a few cases of CHS in which CBF had increased less than 
100% have been reported (Karapanayiotides et al, 2005; Henderson et al, 2001). Thus, other 
factors must be involved in CHS (Hosoda et al, 2003; Kaku et al, 2004; Ogasawara et al 2003; 
Suga et al, 2007; Yoshimoto et al, 1997).  
All authors agree that it is very likely that there has to be damage to cerebral autoregulation, 
in other words, impaired cerebral vasoreactivity (CVR), for CHS to occur (Keunen et al, 
2001). 
Cerebral hemodynamics and CVR are individualized in each patient. This could be 
explained by the different extent of collateral circulation available and by the autoregulatory 
mechanisms of the cerebral circulation. The presence of sufficient collateral circulation has a 
key role in the preservation of CVR, and thus protects against CHS.   
Similarly, other risk factors for CHS are low pulsatility index, severe ipsilateral and 
contralateral carotid disease, and an incomplete circle of Willis (Jansen et al, 1994; Reigel et 
al, 1987; Sbarigia et al 1993). 
CVR makes it possible to keep blood pressure (BP) between acceptable limits (60 mmHg - 160 
mmHg) through arteriolar vasodilatation or vasoconstriction in response to changes in carbon 
dioxide. This response is most pronounced in smaller arteries (diameter 0·5–1·0 mm), whereas 
arteries with a diameter of 2·5 mm or more like the ICA show no substantial change.  
Regulation involves a myogenic and a neurogenic component. In myogenic autoregulation, 
increased intravascular pressure results in vasoconstriction of small arterioles at high 
systemic BP, but when BP exceeds the limit of myogenic autoregulation, the remaining 
autoregulation in small arteries is dependent on sympathetic autonomic innervation. As a 
result of sparse sympathetic innervation, the vertebrobasilar system is less protected than 
other regions of the brain, which explains why this system is more affected in entities like 
hypertensive encephalopathy. Impaired CVR results in failure of the arterial system to 
respond to a sudden increase in CBF and is usually due to severe vascular stenosis together 
with insufficient collateral blood flow. When these two factors coexist, cerebral perfusion is 
maintained by the maximum dilation of the arterioles. This prolonged vasodilation makes 
the vessels unable to respond with vasoconstriction when blood flow is increased, and 
especially when it is increased suddenly (Ascher et al, 2003; Jansen et al, 1994; Reigel et al, 
1987; Tang et al, 2008 Sbarigia et al, 1993).  
At the end of the 1990s, some surgical reports already suggested that patients with 
preoperative hemodynamic failure were at definite risk for CHS (Baker et al, 1998; Cikrit et 
al 1997; Yoshimoto et al, 1997) and that the presence of a critical stenosis in the ICA 
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increased the risk of intracranial hemorrhage (ICH) (Jansen et al, 1994; Macfarlane et al, 
1991; Ouriel et al, 1999; Sbarigia et al, 1993). Preoperative significant reduction in flow 
velocity compared with baseline values is indicative of hypoperfusion and is associated with 
postoperative hyperperfusion (Keunen et al, 2001). 
Sudden revascularization brought about by angioplasty leads to dysfunction of the blood-
brain barrier after the failure of arteriolar vasoconstriction. This results in transudation of 
fluid into the pericapillary astrocytes and interstitium, giving rise to vasogenic edema. This 
hydrostatic edema predominantly affects the vertebrobasilar circulation territory in both 
CHS and hypertensive encephalopathy, possibly as a result of regional variation in cerebral 
sympathetic innervation. 
The most extreme form of this syndrome is bleeding, either ICH, which results in high 
morbidity and mortality, or subarachnoid hemorrhage (SAH), which has a better prognosis.  
The pathophysiology of the hemorrhage that results from revascularization might be 
different from that of CHS described by Sundt, et al (1981). Some authors (Karapanayiotides 
et al, 2005) prefer to call this entity “reperfusion syndrome” to emphasize the damage to 
tissues caused by simple reperfusion. Several investigators have analyzed the characteristics 
of this ICH when it appears in the first few hours and without prodromes, attributing it to 
the rupture of deep penetrating arteries as a result of the sudden normalization of the 
pressure of cerebral perfusion after angioplasty, similar to what occurs in hemorrhage due 
to hypertension (Buhk et al, 2006; Coutts et al, 2003).  
Many cases of SAH after CAS have been reported (Abou-Chebl et al, 2004;  Coutts et al, 
2003; Hartmann et al, 2004; Ho et al, 2000; McCabe et al, 1999; Meyers et al, 2000; Morrish et 
al, 2000; Nikolsky et al, 2002; Pilz et al, 2006; Qureshi et al, 2002); these have a better 
prognosis than ICH.  
It is logical to assume that CBF increases substantially after CAS in a severely stenosed 
carotid artery. However, studies show that the increase in CBF is actually related to 
impaired CVR. In a study by Hosoda et al (1998) CBF significantly increased on the first 
postoperative day in subjects with reduced preoperative CVR but not in those with normal 
preoperative CVR. Similarly, in a study of 23 patients, Ko et al (2005) were unable to 
demonstrate a relation between the degree of stenosis and the increase in CBF. In short, the 
degree of stenosis cannot be considered a key risk factor for CHS, although some series have 
taken it into account.  
Ascher et al (2003) studied 455 patients undergoing CEA and found no relation between 
CHS and the severity of ipsilateral or contralateral carotid stenosis, arterial hypertension, or 
perioperative perfusion pressure. However, mean ICA volume flow and peak systolic 
velocity measured at the onset of symptoms in the 9 CHS cases were higher than in the 
remaining 446 cases. 
In most cases of symptomatic carotid stenoses due to a hemodynamic mechanism CVR is 
also deficient, so it is logical to think that they will be more susceptible to developing CHS 
after revascularization (Brantley et al, 2009). However, in a study of 333 patients undergoing 
CAS, Karkos et al (2010) found no significant differences between symptomatic and 
asymptomatic patients.  
Fukuda et al (2007) carried out an interesting study of CBF and cerebral blood volume 
(CBV) in 15 patients without contralateral carotid stenosis undergoing CEA.  They observed 
a correlation between increased CBV and increased CBF after CEA on single-photon 
emission computed tomography (SPECT) and magnetic resonance imaging (MRI), with 
signs of hyperperfusion in seven patients (47%). Two of these seven patients developed 
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CHS, whereas none of the eight patients with normal CBV developed CHS. In this study, 
elevated preoperative CBV was the only significant independent predictor of post-CEA 
hyperperfusion.   
The endothelial damage caused mainly by chronic hypertension in the small arteries may 
also be related to cerebral autoregulation (Skydell et al, 1987). In fact, some authors relate a 
history of stroke with a greater risk of CHS (Chamorro et al, 2000; McCabe et al, 1999).  
Another important but not essential factor associated with CHS is high blood pressure. High 
blood pressure is the only factor we can treat, so it has become the principal target for 
prevention and treatment. Indeed, the pathophysiology of CHS is similar to that of 
hypertensive encephalopathy in which the blood-brain barrier ruptures as a consequence of 
severe hypertension. Furthermore, histologic changes like fibrinoid necrosis and petechial 
hemorrhage also occur in both hypertensive encephalopathy and CHS (Bernstein et al, 1984; 
Mansoor et al, 1996; Schwartz 2002; Vaughan & Delanty, 2000).  
The mechanisms by which BP increases after carotid revascularization are poorly 
understood. The baroreceptor reflex might break down after receptor denervation after CEA 
or CAS, and hypertension accompanying this feature might increase cerebral perfusion 
which is more evident after bilateral carotid surgery (Ahn et al, 1989; Bove et al, 1979; 
Timmers et al, 2004) and is reported in 19% to 64% after CEA.  
The stimulation of these baroreceptors in the carotid bifurcation during angioplasty can 
cause transient bradycardia and hypotension  that can be followed by rebound 
hypertension. Other phenomena proposed to explain the high blood pressure include 
increased norepinephrine levels probably related to cerebral edema and increased 
intracranial pressure, the release of vasoactive neuropeptides, the use of anesthetic drugs, 
and perioperative stress (Bajardi et al, 1989; Benzel & Hoppens, 1991; Macfarlane et al, 1991; 
Towne JB & Bernhard, 1980; Skydell et al, 1987; Skudlarick & Mooring, 1982;). 
Another possible mediator of impaired autoregulation in CHS is nitric oxide, which causes 
vasodilatation and can increase the permeability of cerebral vessels. Increased nitric oxide 
levels during clamping of the ICA and increased oxygen-derived free radicals produced 
during the restoration of cerebral perfusion are involved in endothelial dysfunction and 
deterioration of autoregulatory mechanisms after CEA (Suga et al, 2007). Several authors 
(Ogasawara et al, 2004; Saito et al, 2007) have reported that the degree of reactive oxygen 
species production after ischemia and reperfusion during CEA depends on the intensity of 
cerebral ischemia during ICA clamping.  
Reactive oxygen species can play a role in the pathogenesis of post-CEA hyperperfusion, 
leading to widespread endothelial damage in the ipsilateral cerebral arteries and thereby 
increasing the risk of ICH in the early postoperative period. Furthermore, administering a 
free-radical scavenger can prevent CHS, providing additional support for this mechanism 
(Ogasawara et al, 2004). 
Finally, an axon-like trigeminovascular reflex has been implicated in the pathophysiology of 
CHS (Macfarlane et al, 1991). The release of vasoactive neuropeptides from perivascular 
sensory nerves via axon reflex-like mechanisms has a significant bearing upon a number of 
hyperperfusion syndromes. 
3. Clinical presentation  
The typical clinical presentation of CHS combines symptoms due to ICH and those due to 
brain damage caused by vasogenic edema. The most common symptoms caused by ICH are 
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headache, confusion, altered levels of consciousness, and sometimes vomiting. On the other 
hand, the edema usually manifests as a neurological deficit on the side of the untreated 
carotid artery, often associated with epileptic activity (seizures, usually starting as partial 
seizures). Arterial hypertension is the norm in patients that develop symptoms of CHS; 
however, it is important to remember that bradycardia and hypotension often occur initially 
after angioplasty due to stimulation of the baroreceptor reflex.  
When a patient has symptoms of neurological deficit after angioplasty, the first diagnosis 
considered is embolic stroke from carotid plaque broken off during the procedure. Thus, 
CHS can mimic a stroke or transient ischemic attack (TIA), so it is important to take into 
account symptoms like headache, seizures, and altered mental status that can suggest CHS. 
Nevertheless, acute neurological deficit accompanied by headache or even seizures is 
obviously compatible with ICH, which can be ruled out only by neuroimaging.  
Neurological deficit due to vasogenic edema is usually transitory, given the absence of 
ischemic infarction (Bernstein et al, 1984; Piepgras et al 1988; Reigel et al, 1987; Sundt et al, 
1981; Solomon et al, 1986). Although the neurological symptoms can vary, the most common 
are visual or motor deficits and aphasia. Other, rarer, symptoms include psychotic 
alterations or mild cognitive deficit (Ogasawara et al, 2005). 
Seizures are generally partial at first and sometimes become generalized later, although 
generalized seizures can also occur initially (Ho et al, 2000); in fact, even status epilepticus 
has been reported up to two weeks after the procedure (Kaku et al, 2004). One third of 
patients with CHS after CEA have seizures without hemiparesis, another third have 
hemiparesis without seizures, and another third have both (Bouri et al, 2011).  
Curiously, the onset of symptoms after CEA and CAS differs. Symptoms usually do not 
appear until three to six days after CEA. In contrast, symptoms usually appear within a few 
hours of CAS. Ogasawara et al (2007) report that the incidence of CHS peaks six days after 
CEA and 12 hours after CAS. After reviewing 36 studies, Bouri et al (2011) concluded CHS 
peaks five days after CEA and the latest case occurred after 28 days.  
The same is true of ICH, which appears 10.7 ± 9.9 days after CEA and 1.7 ± 2.1 days after 
CAS, peaking in the first 12 hours. Tan et al (2004) studied the appearance and onset of 
complications after CAS in 201 patients; they report 10 cases with  TIA (4.9%), 5 of which 
occurred more than 48 hours after the procedure, and 8 strokes (3.9%), 5 of which occurred 
between 2 and 19 days after the procedure. Curiously, however, these authors found no 
cases of CHS. 
The headache in CHS is usually moderate to severe and throbbing, similar to a migraine 
headache (Coutts et al, 2003), and it usually affects the same side as the artery treated.  
Headache may be the only manifestation of CHS (Connolly 2000; Ouriel et al, 1999; Sbarigia 
et al, 1993), so occasionally it has been considered a diagnostic criterion. After CEA, 
headaches are reported in 20% of patients without CHS, in 59% of those with CHS, and in 
84% of those with ICH (Bouri et al, 2011). 
Postprocedural hypertension is a critical, though not essential, finding associated with CHS 
(Solomon et al, 1986; Schroeder et al, 1987; Ouriel et al 1999). Bouri et al review (2011) found 
that the mean systolic BP of CHS cases was 189 mmHg at presentation, and the proportion 
of patients with severe hypertension was significantly higher in patients who developed 
CHS after CEA than in those who did not.  
Hypotension occurs immediately after CAS in 19% to 51% of patients. It is usually transient 
and rarely symptomatic, although it lasts longer than 24 hours in nearly 5% of patients. 
Bradycardia is also common, with an incidence of 3% to 37% in patients administered 
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prophylactic atropine and of 20% to 60% in series with no use of prophylactic atropine. 
Increased age, symptomatic lesions, presence of ulceration and calcification, and carotid 
bulb lesions are significant predictors of bradycardia during CAS (Cayne et al, 2005; Lin et 
al, 2007; Pappada et al, 2006 & Taha et al, 2008). 
Another complication with more dramatic consequences is ICH, which affects less than 1% of 
patients after CEA and between 0.36% and 4.5% after CAS. Generally, ICH has a poor 
prognosis, with a 37% to 80% mortality rate and a 20% to 30% risk of poor recovery in 
survivors after CEA (Piepgras et al,1988; Connolly 2000) and similar consequences after CAS.   
4. Diagnosis 
The diagnosis of CHS is based on the initial suspicion arising from the characteristic triad of 
headache, focal neurological deficit, and seizure after arterial revascularization. The 
differential diagnosis should include stroke and TIA. Seizures and altered consciousness 
favor the diagnosis of CHS. After the initial clinical suspicion, neuroimaging plays a crucial 
role because in addition to ruling out ischemic and hemorrhagic lesions it can reveal 
characteristic signs of hyperperfusion.  
Given the widespread availability of CT, any acute neurological event after 
revascularization is usually studied with this technique. CT is most useful for ruling out 
hemorrhagic processes. Given that the initial symptoms of CHS can mimic stroke or TIA, CT 
can give us clues that argue against an ischemic stroke, because CT findings are usually 
normal after a TIA and are often normal within hours after a stroke. Diffusion MRI is the 
technique of choice to rule out acute ischemic stroke; MRI has shown that there are a greater 
number of embolic lesions up to 48 hours after CAS, although nearly all are asymptomatic 
(Rapp et al, 2007).  
We will comment on two important aspects of neuroimaging studies. First, we will discuss 
their usefulness in the diagnosis of CHS, as apart from demonstrating typical findings like 
vasogenic edema (Case 1) they also enable CBF to be quantified (increases in CBF > 100% 
with respect to baseline values have been related to greater risk of developing CHS). Second, 
we will discuss the usefulness of these techniques in the evaluation of CVR, the key 
pathophysiological factor in CHS.   
4.1 Diagnosing cerebral hyperperfusion 
The imaging techniques that can demonstrate hyperperfusion are single-photon emission 
computed tomography (SPECT), positron emission tomography (PET), transcranial Doppler 
(TCD), CT and MRI. According to Penn et al (1995), xenon-enhanced CT is the best method 
for demonstrating hyperperfusion. Nevertheless, SPECT and TCD are the most common 
methods in the literature, followed by CT and MRI.  
CT in CHS typically reveals ipsilateral sulcal effacement and cerebral edema immediately 
following the onset of symptoms; these findings are considered indirect signs of 
hyperperfusion. CT findings early after the onset of symptoms can be completely normal, 
even when SPECT shows hyperperfusion.  
Without doubt, T2-weighted and FLAIR MRI sequences are more precise in demonstrating 
areas of cerebral edema, and diffusion-weighted MRI makes it possible to rule out 
hyperacute ischemic lesions.  
However, normal findings on MRI do not exclude the presence of CHS. Both MRI and CT 
enable angiographic maps to be constructed to rule out arterial occlusions and perfusion 
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maps can show local hyperemia. Karapanayiotides et al (2005) reported no abnormalities on 
diffusion-weighted MRI in patients with CHS after CEA, ruling out acute ischemia; 
however, perfusion sequences revealed differences in CBF between the hemispheres.  
Hypoperfusion before revascularization and especially hyperperfusion (increase in CBF > 
100% with respect to baseline values) after revascularization are conditions that are closely 
related with CHS. TCD is the method most often used to detect these conditions because it 
enables variations in CBF to be calculated in real time. TCD has many advantages and 
multiple indications in cerebral vascular disease (Alexandrov et al, 2010). TCD monitoring 
can provide direct and real-time information on MCA flow indicative of preoperative 
cerebral hypoperfusion, CVR, postoperative hyperperfusion, and emboli after CEA and 
CAS. Moreover, TCD is widely available, noninvasive, and reproducible. It is important to 
do a baseline study to enable flow velocities before and after revascularization to be 
compared (Dalman et al, 1999; Jansen et al, 1994).  
Asher et al (2003) studied 455 patients undergoing CEA and reported a significant increase 
in mean ICA flow volume in all patients with CHS during the symptomatic period; 
moreover, after flow velocities return to normal, the symptoms of hyperperfusion 
disappear.  
Diverse publications about patients undergoing CAS emphasize the role of TCD in detecting 
hemodynamic changes that make it possible to select patients with greater risk of 
developing CHS. For example, in one interesting study published recently, Kablak et al 
(2010) monitored both MCAs before and after CAS, finding a relation between ICH in 3 
patients and an increase in peak systolic velocities in both MCAs after CAS. Fujimoto et al 
(2004) examined the changes in the MCA mean flow velocity measured by TCD before and 4 
days after CEA. They reported a significant correlation between changes in mean flow 
velocity and changes in regional CBF; mean flow velocity increased more than 50% in all 
cases of CHS.  
Some studies have used both TCD and SPECT to assess patients before and after 
revascularization. Recently, Iwata et al (2011) used these two techniques to study 64 patients 
and found 9 patients who fulfilled the clinical criteria for CHS. These authors relate CHS 
with decreased CVR and changes in MCA flow velocity after angioplasty.  
Perfusion CT has also contributed to our understanding of CHS. Tseng at al (2009) used CT 
to study 55 patients with symptomatic stenoses >70% of the ICA, analyzing absolute values 
of CBV, mean transit time (MTT), and CBF. Three (5%) of 55 patients had CHS after CAS. 
The only significant factor related to the occurrence of CHS was MTT. An MTT cutoff of 3 
seconds distinguished between the occurrence and absence of CHS. MTT prolongation is 
proportional to the degree of stenosis and decrease in blood flow (Maeda et al, 1999; 
Lythgoe et al, 2000; Soinne et al, 2003). Findings of decreased CBF together with MTT 
prolongation and a slight increase in CBV indicate that blood vessels are dilated, thus 
confirming that the autoregulation mechanism is impaired.  
Several authors have examined the role of CT and MRI in demonstrating hyperperfusion 
(Adhiyaman & Alexander 2007; Imai et al 2005; Sundt et al, 1981). Multislice dynamic 
susceptibility contrast MRI or perfusion-weighted MRI can also be used in the preoperative 
assessment of CBF (Fukuda et al, 2007; Wiart et al 2000). Perfusion sequences, however, are 
not quantitative and can only help in the absence of contralateral ICA stenosis.  
PET has also provided valuable information about CHS. Matsubara et al (2009) used PET to 
study patients before and after angioplasty. They found that the vascular reserve tended to 
improve gradually after CAS, while CBF, cerebral perfusion pressure, and cerebral 
www.intechopen.com
Angioplasty, Various Techniques and Challenges in  
Treatment of Congenital and Acquired Vascular Stenoses 
 
16
metabolic rate of oxygen increased rapidly and peaked soon after CAS. These results 
suggest that a large discrepancy between rapidly increased CBF, perfusion pressure, and a 
small increase in vascular reserve in the acute stage after CAS could cause CHS. 
Cerebral oxygen saturation can serve as an indirect measure of CBF. Clinically, regional 
cerebral oxygen saturation can be monitored using transcranial near-infrared spectroscopy, 
which enables noninvasive continuous real-time detection of changes in the ratio of 
oxyhemoglobin to deoxyhemoglobin in the frontal cortex, an indirect measure of cerebral 
oxygenation. Recently, a strong linear correlation was reported between increased 
transcranial regional cerebral oxygen saturation and increased CBF after CEA (Ogasawara et 
al, 2003). When compared with SPECT, the sensitivity and specificity of transcranial regional 
cerebral oxygen saturation for the detection of hyperperfusion were 100%. Transcranial 
near-infrared spectroscopy can demonstrate decreased cerebral oxygenation resulting from 
ICA clamping (Beese et al, 1998; Duncan et al, 1995; Kirkpatrick et al, 1995; Samra et al, 1996) 
and can predict post-CEA CHS. Matsumoto et al (2009) used transcranial near-infrared 
spectroscopy to study 64 patients undergoing CAS, two of whom developed CHS 
(diagnosed by increased CBF at SPECT the day after treatment). An increase in regional 
oxygen saturation > 24% three minutes after revascularization was associated with the 
development of CHS (with impaired CVR). In contrast, in patients without CHS, the normal 
upper limit of the change in regional oxygen saturation three minutes after revascularization 
was 10 %.  
Oxygen saturation should be monitored for a prudential time because bradycardia and 
hypotension often occur with CAS and can occasionally lead to low initial values. As occurs 
in many studies, the small number of patients with CHS in this study does not allow clear 
conclusions to be drawn; nevertheless, given that transcranial near-infrared spectroscopy  
is noninvasive and easy to perform, it should be considered for monitoring patients at risk 
for CHS.  
Alternative methods have been applied to identify risk factors for postoperative 
hyperperfusion, but their utility is not yet clearly established. Electroencephalography is 
used for neurological monitoring during CEA, but it is of low predictive value for CHS 
(Reigel et al, 1987). Nicholas et al (1993) reported that a postoperative increase in ocular 
blood flow greater than 204% measured by ocular pneumoplethysmography is associated 
with a high risk for CHS.  
4.2 Diagnosing hemodynamic reserve 
One strategy that is key to preventing CHS is the study of CVR, which is usually done by 
TCD and SPECT.  
SPECT is sensitive for recognizing CHS, differentiating between ischemia and 
hyperperfusion, and identifying patients at risk for hyperperfusion after CEA (Hosoda et al, 
2001; Naylor et al, 2003; Sfyroeras et al, 2006). Several studies using SPECT have 
demonstrated that decreased CVR using acetazolamide is a significant predictor of post-
CEA hyperperfusion (Ogasawara et al, 2003; Yoshimoto et al, 1997).  
Fewer studies have focused on patients undergoing CAS. Kaku et al (2004) published one of 
the first studies about predicting CHS with nuclear medicine techniques in patients 
undergoing CAS.  
They measured resting CBF and CVR to acetazolamide to evaluate CVR, using split-dose [123I] 
iodoamphetamine SPECT before and 7 days after CAS in 30 patients with critical carotid 
stenosis. The 3 patients with hyperperfusion all had impaired CVR and asymmetrical carotid  
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Case 1 
A 71-year–old man with symptomatic pseudo-occlusion of the right ICA had a seizure  
with Todd´s paralysis six days after CEA. Neuroimaging showed vasogenic edema  
(1- CT, 2- Axial T2-weighted MRi, 3-Coronal FLAIR MRi, 4- Axial diffusion-weighted MRi, 
5- CT angiography) 
CBF.  These authors determined that pretreatment resting CBF value, degree of carotid 
stenosis, and interval from the onset of ischemic symptoms were not significant risk factors.  
However, the high cost and limited availability of SPECT preclude its clinical use.  
TCD has numerous advantages in diagnosing hemodynamic reserve: it is noninvasive, 
relatively simple, cheap, and reproducible, and it is risk free when the breath-hold and 
hyperventilation method is used. TCD enables CVR to be calculated using stimuli like 
hypocapnia (induced by breath holding or by inhalation of CO2) or acetazolamide.  
The response to these stimuli reflects the cerebral autoregulation capacity and thus makes it 
possible to determine which patients have a high risk of developing CHS (Sfyroeras 2006, 
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2009). However, TCD has some drawbacks. The absence of a cranial window makes TCD 
impossible in 15% of patients, mainly elderly women. Moreover, TCD is operator-
dependent and the results also depend on anatomic variants, the degree of collateralization, 
and contralateral ICA occlusion or stenosis.  
Table 1 shows the formulas to calculate the CVR using breath-holding and CO2 inhalation 
or acetazolamide. In the breath-hold method, patients are asked to hold their breath for at 
least 30 seconds during continuous MCA flow velocity monitoring; normal values are 1.2 
+/- 0.6% / sec. In the hyperventilation/ breath-holding method, patients are asked to 
hyperventilate for 40 seconds followed by a breath-holding phase of at least 30 seconds. 
Flow velocity values under maximal hyperventilation and hypoventilation are compared; a 
relative difference greater than 15% argues against relevant impairment of CVR. 
 
 
                       Breath-holding index (BHI) 
 
                             V apnea  - V baseline 
               BHI =     -------------------------  x 100 
                             V baseline x T apnea 
---------------------------------------------------------------------------- 
                   CO2 inhalation test/acetazolamide test 
 
                           CO2/acetazolamide – V baseline 
             CVR =     --------------------------------------    x 100%) 
                                         Vbaseline 
 
Table 1. 
Chang et al (2009) used functional MRI to assess baseline CVR and changes in CBF after 
CAS. Although this small series of 14 patients had no cases of CHS, this study revealed that 
after CAS early CBF changes on the lesion side are more prominent in patients with 
impaired CVR. Therefore, baseline CVR might predict early CBF increase after CAS. New 
MRI techniques like dynamic susceptibility contrast MRI or perfusion-weighted MRI can 
determine CVR (Wiart et al, 2000).  
5. Incidence and risk factors  
This section reviews the incidence of CHS after CAS in the most relevant series included in 
PubMed from 2003 to April 2011. We focus on three aspects of CHS: extracranial CAS, 
angioplasty of intracranial arteries (including the ICA) with or without stenting, and 
cerebral hemorrhage, the most-feared complication of this treatment.  
5.1 Extracranial carotid angioplasty 
Most articles about CHS refer to CAS or CEA of the ICA because occlusive disease is more 
prevalent in these arteries than elsewhere. Bouri et al (2011) reviewed 36 studies of patients 
undergoing CEA and found 1% incidence of CHS and a 0.5% incidence of ICH.  
In many CAS series, patients referred for endovascular treatment comprise a high-risk 
cohort of suboptimal candidates for conventional surgical management. This might partially 
www.intechopen.com
 
Cerebral Hyperperfusion Syndrome After Angioplasty 
 
19 
explain the greater number of complications, including CHS, in patients treated with CAS. 
Furthermore, the endovascular procedure is performed with stricter antithrombotic 
management, with anticoagulation and dual antiplatelet treatment that might lead to a 
higher rate of hemorrhagic events, although not all authors agree with this hypothesis 
(Abou-Chebl et al, 2004; Meyers et al, 2000). Table 2 lists risk factors for CHS, broken down 
into modifiable and non-modifiable factors.  
Although procedural and midterm complication rates of CAS in elderly patients are 
acceptable, high age seems to be a possible risk factor for CHS (Kadkhodayan et al, 2007). 
Other risk factors often mentioned in the literature are severe (>90%) ipsilateral stenosis, 
impaired collateral flow secondary to advanced occlusive disease in other extracranial 
cerebral vessels or an incomplete circle of Willis, perioperative and postoperative 
hypertension, and the use of antiplatelet agents or other anticoagulants (Chamorro et al, 
2000; Reigel et al, 1987; Sfyroeras et al 2008; Zahn et al, 2007). 
Abou et al (2004) report a series of 450 patients undergoing CAS where 5 (1.1%) developed 
CHS, 3 of them developed ICH (0.67%), and 2 of them (0.44%) died. All the patients that 
developed CHS had stenoses >90%, contralateral stenoses >80%, and longstanding 
preprocedural hypertension. The authors calculate that in patients with these three 
conditions, the risk of developing CHS was 16%. Only 5.8% of the patients that did not 
develop CHS met these three criteria. The low incidence of CHS in this series might be due 
to the fact that CHS was not diagnosed in cases with headache and vomiting. Two of the 
cases of ICH appeared a few days after CAS and only one occurred immediately after the 
procedure.  
Ogasawara et al (2007) published a series of 4494 patients revascularized with CEA or CAS. 
Of the 1596 patients treated with CEA, 30 (1.9%) developed CHS and 6 of these developed 
ICH (0.4% of the total). Of the 2898 patients treated with CAS, 31 (1.1%) developed CHS and 
21 (0.7% of the total) of these developed ICH. In the group of patients treated with CEA but 
not in those treated with CAS, poor BP control after revascularization correlated with CHS. 
CHS and ICH ocurred significantly earlier after CAS than after CEA. The difference between 
the two procedures in terms of the timing of CHS onset may be explained as follows. First, 
the higher incidence of embolisms after CAS (Roh et al, 2005) might explain how a 
hemorrhagic transformation could occur after the resolution of the embolism in the tissue 
that was damaged; from a pathophysiological point of view, however, this would represent 
hemorrhagic infarction due to reperfusion rather than CHS. Second, the higher incidence of 
bradycardia and hypotension after the stimulation of the carotid baroreceptors during CAS 
(Mendelsohn et al, 1998; McKevitt et al, 2003; Qureshi et al, 1999) can favor cerebral ischemia 
and CHS after severe rebound hypertension (Abou-Chebl et al, 2007). In an earlier 
publication (Ogasawara et al, 2003), these authors suggested that SPECT findings of 
hyperperfusion continuing at least three days after revascularization predisposes to CHS.  
In an excellent review of 9 studies of CAS comprising a total of 4446 patients, Moulakakis et 
al (2009) found the incidences of CHS and ICH were 1.16% (range, 0.44% - 11.7%) and 0.74% 
(range, 0.36% -4.5%), respectively. Table 3 shows the incidence of CHS and of ICH in the 
largest series published before 2010, including series of patients undergoing angioplasty of 
intracranial arteries.   
In order to document the incidence of CHS after CAS and to determine possible 
predisposing factors, Sfyroeras et al (2009) studied 29 patients with CT, MRI, TCD including 
assessment of CVR, and SPECT before and after the procedure. A total of 5 patients 
developed adverse neurological events. Two of them developed CHS (6.9%); both had 
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exhausted CVR in the preoperative TCD examination. All studies that investigate CVR 
before treatment have found a relation between impaired CVR and the risk of CHS. 
Brantley et al (2009) studied 482 patients, 7 (1.45%) of whom developed CHS after CAS. 
None had an ICH and all recovered within 6 to 24 hours. All had been classified as high risk 
for CEA, and CHS was more common in those with a previous TIA. The absence of ICH was 
probably related to the fact that 64% of the patients had asymptomatic stenoses. These 
authors found no significant relation between CHS and risk factors reported in other series 
like hypertension, high-grade ICA stenosis, and contralateral disease. The postprocedural 
BP in the CHS cohort tended to be higher than in the other patients, but this difference did 
not reach statistical significance. 
 
Potential risk factors for CHS 
Modifiable                                                    Not modifiable 
 
High blood pressure                                    Diminished CVR   
Excessive administration of antithrombotic drugs         Hypertensive microangiopathy 
Simultaneous revascularization of multiple vessels       Recent minor stroke 
Use of high doses of volatile halogenated                  Age >70 years 
hydrocarbon anesthetics 
 
Recent (<3 months) contralateral CEA                      High grade carotid artery stenosis 
                                                                                                   Incomplete circle of Willis  
                                                                                                   Contralateral carotid occlusion 
                                                                                                   Poor collateral flow 
                                                                                                          Increase in regional cerebral  
                                       oxygen saturation  >24% 
                                                                                                          Diabetes mellitus, Hypertension 
                                                                                                   Increase in perfusion >100% 
                                                                                                   Preoperative hypoperfusion 
Table 2. 
Grunwald et al (2009) report a series of 417 patients treated with CAS in whom BP was 
meticulously controlled during the first 24 hours; furthermore, MRI was performed before 
and after the procedure in 269 cases. The mean degree of carotid stenosis was 87%, and 65% 
of the patients were symptomatic. Of the 10 (2.4%) patients who developed CHS, seven had 
excessive small vessel disease with old territorial infarcts or freshly demarked lesions. Small 
vessel disease is considered a risk factor for CHS because it impairs the capacity of these 
arteries to contract. Curiously, none of these patients had severe hypertension. In three 
cases, ICH occurred within a few hours of CAS, and all of these had extensive microvascular 
changes and impaired collateral blood flow due to high-grade stenosis (>80%) of the 
contralateral ICA. However, 23% of the patients that did not develop CHS also had high-
grade stenosis of the contralateral ICA. On MRI, all had increased signal intensity in the 
subarachnoid space on the same side as the stented ICA, which resolved within 3–5 days.  
Curiously, this study was unable to demonstrate a relation between CHS and factors like 
postprocedural hypertension, advanced age, degree of ipsilateral stenosis, or contralateral 
disease.  
Regarding prior stroke as a risk factor for CHS, many authors have found that diseases like 
diabetes mellitus or longstanding pre-existing hypertension in which microangiopathy 
affects the endothelium of small vessels predispose to hyperperfusion and CHS (Chamorro 
et al, 2000; McCabe et al, 1999; Naylor et al, 2003; van Mook et al, 2005). 
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Tietke et al (2010) analyzed the outcomes of 358 patients treated with CAS using small 
closed-cell stents without distal protection. The peri-interventional and 30-day 
mortality/stroke rate was 4.19% (15/358). These events included 3 deaths, 5 CHS 
(comprising one death by a secondary fatal ICH), one SAH and 7 ischaemic strokes. All but 
one of the patients with CHS had an initial stenosis of >90%; the remaining patient had an 
initial stenosis of 50% to 70% and was the only one with CHS without ICH. The patient who 
died was the only woman with CHS and she also had an occluded contralateral ICA. Most 
complications occurred in initial symptomatic patients (5.36%).  
The risk of CHS related to the type of protection (proximal or distal) has not been 
thoroughly studied. Pieniazek et al. (2004) compared the complications in 135 patients 
undergoing CAS, 42 with proximal protection and 93 with distal protection, but only one 
case of CHS developed.   
Bilateral carotid stenoses are generally treated in two separate stenting procedures to 
minimize hemodynamic impairment from stimulation of the carotid sinus baroreceptor 
reflex (severe bradycardia, hypotension) and the risk of CHS. As we explained in section 2 
(pathophysiology), the baroreceptor reflex might break down after receptor denervation 
after CEA or CAS; this is more common after bilateral carotid surgery, and accompanying 
hypertension might increase the risk of CHS.  
 
 
Author / Year Patients CHS (%) ICH (%) 
Meyers / 2000 140 7 (5%) 1 (0.7%) 
Coutts / 2003 44 3 (6.8%) 2 (4.5%) 
Abou / 2004 450 2 (0.44%) 3 (0.67%) 
Kaku / 2004 30 1 (3.33%) 0% 
Imai / 2005  17 2 (11.7%) 2 (11.7%) 
du Mesnil de Rochemontn / 2006 50 1 (2%) 0% 
Kablak-Ziembicka / 2006 92 2 (2.2%) 2 (2.2%) 
Abou / 2007  836 8 (0.96%) 3 (0.36%) 
Ogasawara / 2007  2989 31 (1.1%) 21 (0.7%) 
Sfyroeras / 2008  29 2 (7%) 0% 
Brantley / 2009 482 7 (1.5%) 0% 
Grunwald / 2009 417 7 (1.7%) 3 (0.7%) 
Tietke et al (2010) 358 4 (1.1%) 1 (0.27%) 
Karkos et al (2010).  316 10 (3%) 0% 
 
Table 3. Incidence of hyperperfusion syndrome, and intracranial hemorrhage after CAS in 
the reviewed series from 2003 to 2010 
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Few studies have addressed the subject of simultaneous bilateral CAS. Henry et al. (2005) 
reported a series of 17 patients who underwent simultaneous bilateral CAS and 40 patients 
who underwent bilateral CAS in a staged manner (among these 40 patients 10 underwent 
the second procedure 24 hours after the first, while the other 30 underwent the second 
procedure from 2 days to 2 months after the first). Two cases of CHS occurred, one each 
group, although the patient in the simultaneous treatment group who developed CHS died. 
Lee et al. (2006) found no CHS in a series of 27 patients who underwent bilateral CAS. 
Diehm et al. (2008) studied patients treated with bilateral CAS with at least one month 
between procedures and reported no significant differences in complications compared to 
patients treated with unilateral CAS.   
An interesting study that deals with pseudo-occlusive carotids was published by Choi  
et al (2010). These authors analyze the outcome after CAS in 48 patients with nearly 
occlusive stenosis of the ICA. The procedural success rate was 98% and a good outcome  
at six months (modified Rankin scale ≤2) was achieved in 44 patients (92%). Four (8%) 
patients developed CHS.  
Another interesting article was published by Karkos et al (2010). They studied the 
complications in the first 30 days in 333 angioplasties in 316 patients, 35% of whom had 
symptomatic carotid disease. Perioperative neurological events included stroke in 6 patients 
(1.8%), TIA in 15 (4.5%), and CHS in 10 (3.0%). The incidence of CHS did not differ between 
the group of patients with symptoms and those without. Bradycardia was noted in 48 
patients (14%) and hypotension in 45 (13%), and two of these patients (0.6%) required 
admission to the intensive care unit for hemodynamic instability. Curiously, the only factors 
related to increased morbimortality were hyperlipidemia and current or previous smoking. 
5.2 Angioplasty in intracranial arteries  
As is to be expected, fewer studies have addressed CHS in relation to intracranial 
angioplasty because this procedure is newer than angioplasty in extracranial arteries. In this 
section, we will discuss the most interesting series and cases of patients treated with this 
technique. In 2000, Meyers et al reported the first SAH due to stenosis of the intracranial 
vertebral artery. In their series of 140 patients treated with CAS (including 10 intracranial 
carotids, 14 intracranial vertebral arteries, 4 basilar arteries, and 1 MCA), the incidence of 
CHS was 5% (7 of 140 patients, 5 carotids and 2 vertebral arteries), one with ICH and 
another with SAH. Importantly, six patients (85%) were symptomatic with crescendo TIAs 
before treatment, and these symptoms were probably related to impaired CVR. The first 
case of CHS with ICH after intracranial MCA angioplasty was reported by Liu et al in 2001. 
One of the first series of patients undergoing intracranial CAS was published by Terada et al 
(2006). These authors reported 106 procedures in 99 patients (57 patients had intracranial 
ICA stenosis, 23 had MCA stenosis, and 19 had vertebrobasilar stenosis). The ICA stenosis 
involved the petrous or cavernous in 47 cases (24 patients were treated with angioplasty and 
23 with stenting). Four hemorrhagic complications occurred in 106 procedures. One patient 
had SAH and the other 3 cases had the following characteristics: severe stenosis with poor 
collateral flow, low perfusion with CVR damage on SPECT, appearance of ICH between 30 
minutes and 16 hours after the procedure, and patient age greater than 70 years. The rate of 
ICH directly related to CAS was 3%. In two of three cases, CHS was strongly suspected from 
the SPECT findings. In the nonhemorrhagic group, hemodynamic compromise was found in 
27 of 47 (57%) patients. 
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It is important to remember that hemorrhage caused by vessel injury is also a possible 
mechanism of hemorrhagic complications. For instance, in the patient with SAH in Terada 
et al (2006) studies, wall dissection, perforation of the vessel wall by the guidewire, or 
rupture of a tiny aneurysm located at the distal part of ICA were not completely ruled out. 
Rezende et al (2006) reported a case of CHS after stenting for intracranial vertebral stenosis. 
They point out the significant hemodynamic component due to the absence of the 
contralateral vertebral artery and collateral supply from the carotid territory.  
More recent articles about intracranial angioplasty show more promising results. Guo et al 
(2010) implanted 53 self-expanding stents with a technical success rate of 98%.  
Complications included SAH (1.9%) and occlusion (3.8%), but there were no cases of CHS.  
Zhang et al (2008) reported the first case of ICH after CAS in both vertebral arteries with 
stenosis >90%. The flow velocity of both vertebral arteries measured by TCD increased more 
than 100% and high BP coincided with the abrupt onset of ICH three hours after the 
procedure.  
In conclusion, the factors involved in the development of CHS after intracranial procedures 
seem similar to those involved in extracranial procedures, and the results of intracranial 
angioplasty are very promising.  
5.3 Intracranial hemorrhage after angioplasty 
ICH is the severest form of CHS and it has the worst prognosis (Case 2). The low incidence 
of ICH and the small number of patients in the various series reported precludes clear 
conclusions about the risk factors involved, although presumably they are the same as those 
involved in CHS. The first question is whether ICH is an extreme consequence of CHS or 
whether it has a distinct pathophysiology. Numerous mechanisms are possible: CHS, 
hemorrhagic diathesis caused by antiplatelet and anticoagulation therapy after stenting, 
hemorrhage around or in a recent infarction or other associated lesion (including 
hypertensive ICH), or rupture of an intracranial aneurysm. 
In an interesting article published in 2003, Coutts et al try to narrow the definition of CHS. 
After studying 129 patients treated with CEA and 44 treated by CAS, these authors 
postulate that three different syndromes can occur in relation to hyperperfusion: acute focal 
edema, acute hemorrhage, and delayed classic presentation described for Sundt et al (1981). 
One of their patients had ICH three hours after CAS in the absence of high BP or symptoms 
suggestive of hyperperfusion. Other authors like Buhk et al (2006) argue for the existence of 
two distinct syndromes: first, classic CHS, in which symptoms of ipsilateral, frontotemporal, 
or retro-orbital headache, neurological deficit, and sometimes seizures typically begin 
between the fifth and seventh days after revascularization, and second, a more dramatic 
clinical presentation with ICH considered as damage due to reperfusion (Imparato et al, 
1984; Takolander & Bergqvist 1983). In many of the cases published, ICH occurred within a 
few hours of the procedure and predominantly affected the basal ganglia; furthermore, all 
the patients in these cases presented with a high-grade stenosis. Therefore, the 
pathophysiology of this type of ICH might differ from that of CHS, being closer to that of 
hypertensive ICH, in this case due to rupture of small perforating arteries in the basal 
ganglia after acute exposure to suddenly normalized perfusion pressure after angioplasty of 
a high grade stenosis.  
Brantley et al (2009) reported a patient with a nearly occlusive ICA stenosis who developed 
a fatal ipsilateral ICH immediately after the intervention; ICH was due to hemorrhagic 
conversion of a prior stroke.   
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The incidence of ICH after CEA in the series published ranges between 0.2% and 0.7% 
(Piepgras et al, 1988; Pomposelli et al, 1988; Solomon et al, 1986; Wilson & Ammar, 2005), 
whereas the incidence of ICH after CAS is higher (Timaran et al, 2009), reaching 5% in some 
series.   
Schoser et al (1997) reported the first case of ICH after CAS, a 59-year-old woman with 
severe stenosis of the left ICA who developed putaminal hemorrhage on the third day after 
the procedure. CT showed an ipsilateral border zone infartion.  
McCabe et al (1999) reported the first fatal case of ICH after CAS, a man with severe stenosis 
who developed ICH within hours of CAS without any prodromes. Mori et al (1999) reported 
a similar case in which ICH affected the basal zones with ventricular and subarachnoid 
extension. Both cases had signs of microangiopathy, which is associated with increased risk 
of ICH (Chamorro et al, 2000; McCabe et al, 1999).  
 
 
Case 2 
1- Angiogram showing 95% stenosis of the left ICA in a patient with 
 occlusion of the right ICA.  
2- Angiogram after left CAS.  
3- No lesions were discernible on the pre-treatment CT .   
4- CT 24 hours later shows extensive hematoma in the left frontal lobe  
(Courtesy of Dr. Carlos Castaño).  
Tan and Phatouros (2009) reviewed 170 patients treated with CAS, 4 (2.3%) of whom 
developed CHS, one of these with cerebral edema, one with petechial hemorrhage, and two 
with ICH, which was fatal in one case. All developed CHS within six hours of the procedure 
and all had stenoses of the internal carotid >95%. Both patients who developed ICH had 
been treated within three weeks after an ischemic event.  
Morrish et al (2000) observed a 4.4% incidence of ICH after 104 CAS in 90 patients; the mean 
ICA stenosis was 95% in those who developed ICH. In two of the patients, who died, ICH 
involved the basal ganglia. In this series, the incidence of ICH may have been increased due 
to a high dose of heparin and the absence of distal protection, given that recent ischemia is a 
risk factor for ICH.  
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Matsuo et al (2000) reported two cases of ICH, one of which affected the basal ganglia the 
day after CAS. The fatal ICH reported by Abou et al (2004) appeared at the level of the basal 
ganglia one hour after CAS. Finally, the series of 161 patients reported by Koch et al (2002) 
included a single case of fatal ICH after CAS in a severely stenosed ICA. Kablak et al (2010) 
reported 3 (1.4%) cases ICH among 210 patients, one of whom had SAH. In their study, 
increased systolic velocity in both MCAs was a clear risk factor, and one of the three patients 
had occlusion or severe stenosis of the contralateral carotid.  
In addition to impaired CVR, the most widely accepted risk factors are insufficient 
intracranial collateralization and signs of cerebral microangiopathy. We know that 
hypertensive encephalopathy does not consist only of periventricular demyelination but 
possibly also includes small areas of perivascular hemorrhage that can be associated with 
higher risk of developing ICH. It also seems that the severity of the stenosis plays an 
important role, as most patients in the literature have severe stenosis.  
6. Contrast-induced encephalopathy  
Neurotoxicity from contrast agents is a rare but well-known complication of diagnostic and 
therapeutic procedures that employ these agents.  
Leptomeningeal enhancement is often reported after CAS due to the abrupt increase in 
blood flow even when this does not cause symptoms (Wilkinson et al, 2000). Nevertheless, 
some authors purport that this phenomenon represents the extravasation of contrast 
material toward the subarachnoid space; Bretschneider and Strotzer (2000) reported 11 
cases, some of which were related to hypoxic brain damage. Ekel et al (1998) reported a case 
of contrast enhancement mimicking SAH, and Mamourian et al (2000) used an animal 
model to demonstrate that contrast material can cross into the cerebrospinal spinal fluid in 
sufficient concentration to alter the appearance of the subarachnoid space on MRI. Dangas et 
al (2001) reported a case of contrast-induced encephalopathy after CAS in an 82-year-old 
man with a TIA and 90% stenosis in the right carotid. Immediately after CAS, this patient 
presented confusion and left hemiparesis in the territory of the right carotid. CT showed 
marked cortical enhancement and edema of the right cerebral hemisphere. The patient 
improved rapidly and by day 2 was completely recovered; MRI found no cortical edema 
and normal sulci.  
Canovas et al (2007) published a case of extravasation of contrast material immediately after 
the rupture of the balloon in a woman with a very calcified plaque (Case 3) in whom the 
pressure of the balloon reached 8 atmospheres. The pressure of the balloon  probably 
magnified the hemodynamic effect, making the extravasation of the contrast material very 
aggressive and giving rise to a clinical picture identical to an embolic stroke of the MCA. As 
in other cases reported in the literature, this patient’s condition improved and the imaging 
findings were normal after 48 h.  
Contrast-induced encephalopathy should be differentiated from the classical CHS described 
Sundt et al (1981), although it probably has a similar pathophysiology. A high dose of 
contrast agent may result in acute breakdown of the blood-brain barrier, allowing the 
contrast material to enter the brain and resulting in the acute development of a dramatic 
clinical presentation. The higher osmolality of ioxaglate compared with blood may in turn 
produce fluid extravasation and cerebral edema. The prognosis is usually excellent, as is 
evidenced by other recently published cases occurring after endovascular procedures 
(Guimaraens et al, 2010, Fang et al, 2009; Paúl et al, 2009).  
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Case 3 
1- Angiogram before left CAS showing 70% stenosis of the left ICA 
2- Angiogram after left CAS  
3- Axial diffusion-weighted MRi showing ipsilateral silent ischemic lesions  
4- CT with extravasation of the contrast 
5- Axial FLAIR MRi  
6- Axial T1-weighted MRi  
7. Prevention and treatment 
It is crucial to identify patients with risk factors for developing hyperperfusion so that 
preventive measure can be taken during and after revascularization. In the previous section, 
we discussed the factors most commonly considered to increase this risk, and in this section 
we discuss the most interesting preventive strategies.  
There is a consensus that the most important risk factors are severely impaired CVR and 
deficient collaterality (severe ipsilateral stenosis, impaired collateral flow, occlusive disease 
in other extracranial cerebral vessels, and incomplete circle of Willis). Other proposed 
factors include advanced age, perioperative and postoperative hypertension, and the use of 
antiplatelet agents or other anticoagulants. Thus, we should concentrate our efforts on the 
factors in which we can intervene. Regarding preventive measures before the procedure, we 
will discuss the assessment of CVR as the primary measure and we will also examine the 
usefulness of assessing the supra-aortic trunks and the circle of Willis.  Regarding 
preventive measures during and after the procedure, we will focus on detecting cerebral 
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hyperperfusion and thus on the importance of strict, prolonged BP control and appropriate 
antithrombotic management.  
As we discussed in the Diagnosis section, various options are available for assessing CVR. 
Probably the most widely available option is TCD, which has many advantages and enables 
us to measure cerebral flow at rest and under certain stimuli (breath-holding, inhalation of 
CO2, intravenous acetazolamide administration). The simplest and most noninvasive TCD 
test is breath-holding with or without hyperventilation (see the Diagnosis section). 
Therefore, the first preventive measure that is recommended before revascularization is 
CVR assessment using TCD (Sfyroeras 2006, 2009).   
It would also be advisable to do a thorough MRI study of the supra-aortic trunks and of the 
circle of Willis as well as a study of the cerebral parenchyma using FLAIR, T2-weighted, and 
diffusion sequences to detect hyperacute lesions and small-vessel disease, which are also 
related to increased risk of CHS. As mentioned in the Diagnosis section, CVR can also be 
assessed by SPECT, CT, and MRI, although these approaches are more expensive and less 
widely available.  
Again, TCD is very useful for monitoring cerebral flow during revascularization 
procedures. In patients undergoing CEA, TCD can detect increases in MCA flow velocity 
greater than 100% during the intervention, thus alerting to a situation of risk. Likewise, TCD 
monitoring during CAS and probably in the hours after the procedure can help select high 
risk patients (Dalman et al, 1999; Fujimoto et al, 2004; Kablak et al, 2010; Jansen et al, 1994; 
Iwata et al, 2011; Sfyroeras et al, 2009).  
Strict control of hypertension is one of the preventive measures that has received the most 
attention. Most Investigators recommend strict control of BP in the postoperative period to 
prevent ICH after CEA (Ahn et al, 1989; Bernstein et al, 1984; Bove et al, 1979; Buhk et al, 
2006; Hosoda et al, 2001; Ko et al, 2005; Roh et al, 2005; Safian et al, 2006; Tang et al, 2008) 
and after CAS, as we will see below.  
It has been suggested that even BP in the normal range may be deleterious in patients at 
high risk for CHS (Piepgras et al, 1988; Ouriel et al, 1999; Jorgensen & Schroeder, 1993).  
Regarding strict control of BP, Abou-Chebl et al (2007) published an interesting study that 
analyzed the presence of CHS and ICH in 836 patients treated with CAS. These authors 
maintained BP < 140/90 mmHg in patients with lower risk and BP < 120/80 mm Hg in 
patients with a treated stenosis ≥ 90%, contralateral stenosis  ≥ 80%, and hypertension (i.e., 
risk factors for CHS). They conclude that comprehensive management of arterial 
hypertension can lower the incidence of ICH and CHS in high-risk patients following CAS, 
without additional complications or prolonged hospitalization. The strict control of BP must 
be maintained until CVR is restored, and this interval varies among patients. Thus, the use 
of TCD to assess the recovery of CVR can probably help guide antihypertensive therapy 
(Buhk 2006). 
Bando et al (2001) reported a stroke patient with a 90% stenosis of the intracranial left 
vertebral artery treated with CAS. Immediately after the procedure, hyperperfusion was 
detected by SPECT and TCD. The patient recovered from CHS quickly after a week’s 
antihypertensive therapy. 
Brus-Ramer et al (2010) published an interesting case of a patient treated with CAS who 
developed signs of hyperperfusion detected by TCD and depicted on angiography as 
hyperintense punctate foci potentially representing small dilations in the vascular territory 
of stented arteries. Lowering BP by 40% probably prevented CHS; thus, in high risk patients, 
aggressive BP management during and after CAS can prevent potentially serious sequelae. 
www.intechopen.com
Angioplasty, Various Techniques and Challenges in  
Treatment of Congenital and Acquired Vascular Stenoses 
 
28
Another aspect that remains to be determined is the most appropriate type of drugs for 
these patients. In this context, it seems logical that drugs that have no direct effects on CBF 
and those that give some degree of cerebral vasoconstriction could be beneficial. Drugs like 
nitroprusside and calcium antagonists that increase CBF should be avoided. The ß 1-
adrenergic antagonists (beta-blockers) reduce BP with little effect on intracranial pressure 
within the autoregulatory range, although they can exacerbate the bradycardia that can 
occur after CAS.  
The mixed alpha-adrenergic antagonist and ß -adrenergic antagonist labetalol, which has no 
direct effects on CBF and decreases the cerebral perfusion pressure and mean arterial 
pressure by about 30% compared with baseline, has successfully been used in CHS after 
CEA (Halliday et al, 2004). The alpha 2-adrenergic agonist clonidine, which is commonly 
used after CEA (associated with raised cranial and plasma catecholamine concentrations), 
has the advantage of decreasing CBF.  
General anesthesia is often unnecessary for CAS.  However, when general anesthesia is 
required, it is important to use anesthetics that do not increase CBF. Studies of CBF during 
surgery have shown that high doses of volatile halogenated hydrocarbon anesthetics may 
lead to the development of CHS (Skydell et al, 1987). Isoflurane is the volatile anesthetic of 
choice in neurosurgery because it results in less pronounced vasodilation than other 
halogenated anesthetics at equipotent doses. The effects of isoflurane on cerebral metabolic 
rate and autoregulation are dose dependent, with impairment of CVR at high doses. 
Propofol has been used in patients with CHS, it normalizes CBF, probably because of its 
effects on cerebral metabolism (Kaisti et al, 2003). 
Safety concerns have been raised about the effects of anticoagulants and antiplatelet agents 
and the risk of ICH following CEA, but no causal link has been found (Ouriel et al, 1999; 
Penn et al, 1995). Likewise, no association between these drugs and ICH has been found in 
patients undergoing CAS (Abou et al, 2003), although some studies have reported higher 
incidences of ICH, probably related to higher than usual doses of anticoagulants (Meyers et 
al, 2000 ; Morrish et al, 2000). 
Levy et al (2002) propose an interesting preventive strategy consisting of performing 
angioplasty in two phases, with posterior stent collocation. These authors published a series 
of 8 cases of intracranial vertebral stenosis with good outcomes despite one case of arterial 
dissection that required stenting. Yoshimura et al (2009) also used two-step endovascular 
treatment in high risk patients with impaired CVR. These authors first performed 
angioplasty with a small balloon (3 mm), and once hyperperfusion improved on SPECT 
about one month later they performed a second, definitive angioplasty with stent 
placement. None of the 9 patients treated with the two-step approach had problems related 
with hyperperfusion (one required stenting for a dissected artery), whereas 5 of the  
9 patients in the control group had hyperperfusion and one had status epilepticus related  
to CHS.  
Additional efforts to reduce the risk of ICH may include limiting the duration of balloon 
inflation and employing emboli-prevention devices, as these practices have been related to 
ischemia with posterior development of ICH  (Jansen et al, 1994; Sakaki et al, 1992; Sundt et 
al 1981). 
An important, somewhat controversial factor is the optimal interval between stroke and 
revascularization. We know that an extensive ischemic lesion represents a greater risk of 
damage due to reperfusion. Furthermore, classically a six-week interval was recommended 
to avoid treatment complications. However, studies like the NASCET show that the benefits 
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of carotid revascularization are greatest in the first two weeks after the event, and the 
subgroup of patients with less risk for early revascularization are those with small ischemic 
lesions and mild neurologic impairment (Keldahl et al, 2010). A recent (<3 months) 
contralateral CEA is an additional potential risk factor for CHS and should also be 
considered in the timing of surgery (Ascher et al, 2003). Very few studies have addressed 
the use of CAS in hyperacute strokes, but those that have report good safety outcome 
(Miyamoto et al, 2008; Setacci et al 2010).  
Some authors (Henry et al, 2005; Lee et al, 2006) claim that treatment of both carotid arteries 
is feasible in carefully selected patients, either in the same procedure or in two procedures 
separated by an interval of one day; these authors report safety and complication rates 
comparable to those of large published series in high-risk patients. Nevertheless, careful 
monitoring of the patient, blood pressure, and heart rate is mandatory to avoid 
complications related to CHS.  
Owing to the presence of free radicals during reperfusion and their relation to post-ischemic 
hyperperfusion, substances like edaravone have been investigated. Edaravone inhibits lipid 
peroxidation and vascular endothelial cell injury, improving edema cerebral and tissue 
injury.  Pretreatment with edaravone decreased the incidence of hyperperfusion after CEA 
as measured by SPECT (Ogasawara et al, 2004).  
Once CHS occurs, aggressive measures to lower BP are imperative. As there are no data 
from randomized trials comparing the optimal perioperative management protocol for 
patients with CHS due to the rarity of this complication, we must focus on controlling BP, 
reducing cerebral edema, and, according to some authors, temporarily withdraw 
antithrombotic therapy. Treatments for cerebral edema include adequate sedation, 
hyperventilation, and administration of mannitol or hypertonic saline. Evidently, there are 
no data to support these treatments in CHS. Corticosteroids and barbiturates have also been 
used in CHS.   
There are no available data recommending prophylactic use of anticonvulsant therapy in 
patients undergoing carotid revascularization; however, in the presence of seizures, 
treatment with anticonvulsants is indicated. 
In conclusion, assessing CVR before treatment and monitoring CBF velocities during and 
after the procedure can help select the patients who need strict control of BP to prevent 
CHS. The optimal BP remains to be determined, but BP should be lowered to below the 
baseline after luminal gain with stenting to prevent secondary injury. Despite the lack of a 
precise BP target, lowering systolic BP to at least 20% to 30% below baseline values seems 
critical, particularly in patients with critical stenosis and above all in patients with impaired 
CVR. Labetalol and clonidine seem to be the most appropriate drugs for BP control in this 
context.  
To determine when discharge is safe after CAS, patients should be divided into two 
groups. One group includes asymptomatic, hemodynamically stable patients with low 
comorbidity who could be discharged after 6 h of observation, according to some authors. 
These patients should be treated using a hemostatic closure device for the arterial 
puncture. The other group includes older patients with associated comorbidity, mainly 
those with altered renal function, those that require anticoagulation, and those with 
altered BP or bradycardia. Finally, it is recommendable to warn the family about 
symptoms that call for re-evaluation, especially seizures, neurological deficit, and 
headaches associated with hypertension. 
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8. Abbreviations 
CHS: Cerebral Hyperperfusion Syndrome 
CBF: Cerebral Blood Flow 
CBV: Cerebral blood volume 
CT: Cranial tomography 
CVR: Cerebral Vasoreactivity 
HTA: hypertension 
ICA: Internal Carotid Artery  
ICH: Intracranial Hemorrhage  
MMT: mean transit time 
MCA: Middle Cerebral Artery  
MRi: magnetic resonance imaging, 
PET: Positron Emission Tomography  
TCD: transcranial doppler 
TIA: Transient Ischemic Attack  
SAH: Subarachnoid hemorrhage 
SPECT: Single-photon emission computed tomography  
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